Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Ottawa
$105,000.00
CD40 ligand as a potential adjuvant for a pan-variant intranasal vaccine against SARS-CoV-2
FY 2023-24
Summary
The COVID-19 pandemic began in December of 2019, following the identification of SARS-CoV-2, an coronavirus with likely zoonotic origins. Vaccination has been instrumental in global efforts to limit the extent of the pandemic, greatly reducing COVID-19-related mortality. Unfortunately, commercial SARS-CoV-2 vaccines have diminished efficacy against emerging variants, necessitating updated vaccine formulations and booster shots. Research into vaccination strategies capable of generating mucosal and variant-proof immunity is critical not only to limit the spread of future SARS-CoV-2 variants, but also for controlling future outbreaks of other viruses. We aim to evaluate the effectiveness of using CD40 ligand, a well-studied vaccine adjuvant, as part of intranasal vaccine formulation against SARS-CoV-2. We will compare the robustness of the vaccine to a traditional intramuscular counterpart, and determine the extent of protection afforded against immune escaping SARS-CoV-2 subvariants. This work will improve our understanding of the mechanisms underlying effective vaccination against SARS-CoV-2, which will be applicable for future emerging respiratory viruses as well.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
497341
Name
Tamming Levi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
CD40 ligand as a potential adjuvant for a pan-variant intranasal vaccine against SARS-CoV-2
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adjuvants; Antibodies; Covid-19; Immunology; Pandemic; Sars-Cov-2; T Cells; Vaccines
Abstract
The COVID-19 pandemic began in December of 2019, following the identification of SARS-CoV-2, an coronavirus with likely zoonotic origins. Vaccination has been instrumental in global efforts to limit the extent of the pandemic, greatly reducing COVID-19-related mortality. Unfortunately, commercial SARS-CoV-2 vaccines have diminished efficacy against emerging variants, necessitating updated vaccine formulations and booster shots. Research into vaccination strategies capable of generating mucosal and variant-proof immunity is critical not only to limit the spread of future SARS-CoV-2 variants, but also for controlling future outbreaks of other viruses. We aim to evaluate the effectiveness of using CD40 ligand, a well-studied vaccine adjuvant, as part of intranasal vaccine formulation against SARS-CoV-2. We will compare the robustness of the vaccine to a traditional intramuscular counterpart, and determine the extent of protection afforded against immune escaping SARS-CoV-2 subvariants. This work will improve our understanding of the mechanisms underlying effective vaccination against SARS-CoV-2, which will be applicable for future emerging respiratory viruses as well.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tamming, Levi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~